Who are rhTPO combined with Herombopag + CsA's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhtpo-combined-with-herombopag-csa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

rhTPO combined with Herombopag + CsA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rhTPO combined with Herombopag + CsA (rhTPO combined with Herombopag + CsA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin receptor agonist combination with immunosuppressant. Area: Hematology/Immunology.

marketed Thrombopoietin receptor agonist combination with immunosuppressant Thrombopoietin receptor (MPL); calcineurin (CsA target) Hematology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

rhTPO combined with Herombopag + CsA (rhTPO combined with Herombopag + CsA) — Peking Union Medical College Hospital. This combination therapy stimulates platelet production through thrombopoietin receptor agonism while suppressing immune-mediated platelet destruction via immunosuppression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rhTPO combined with Herombopag + CsA TARGET	rhTPO combined with Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist combination with immunosuppressant	Thrombopoietin receptor (MPL); calcineurin (CsA target)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin receptor agonist combination with immunosuppressant class)

Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhTPO combined with Herombopag + CsA — Competitive Intelligence Brief. https://druglandscape.com/ci/rhtpo-combined-with-herombopag-csa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab